glp 1 receptor agonists beyond their pancreatic effects GLP-1 are increasingly used to treat type 2 diabetes and obesity, and trials have shown reductions in cardiovascular risk and slowing of kidney failure. Adverse events are mostly gastrointestinal. Read GLP-1 Receptor Agonists in the
Description
This is crucial to control or even avoid type 2 diabetes
The basal insulin/DPP-4 inhibitor combination is a practical and a less complicated treatment option without the need for multiple injections during the day, less need for glucose self-measurements and dose adjustments for insulin (7074)
Until recently, the only effective treatment for obesity was bariatric surgery, and a century of drug development for obesity can be essentially described as a failure until now
PMC 304885
For patients currently on basal insulin or a GLP-1 RA : Start at 16 units subcutaneously once daily without regard to meals
